So HER2CLIMB-04 was presented by Dr. Krop here at ASCO 2021 and it’s a really exciting study because it combines two of our newest approved drugs in the HER2 space together into one trial. So obviously I’m talking about to tucatinib and trastuzumab deruxtecan here. And so trastuzumab deruxtecan is approved third line and beyond for HER2 positive breast cancer, shows an incredibly exciting overall response rate, duration of response, et cetera...
So HER2CLIMB-04 was presented by Dr. Krop here at ASCO 2021 and it’s a really exciting study because it combines two of our newest approved drugs in the HER2 space together into one trial. So obviously I’m talking about to tucatinib and trastuzumab deruxtecan here. And so trastuzumab deruxtecan is approved third line and beyond for HER2 positive breast cancer, shows an incredibly exciting overall response rate, duration of response, et cetera. And then tucatinib is also approved really for second line and beyond in combination with its partner of capecitabine and trastuzumab. Interestingly, a lot of the side effects of the HER2CLIMB regimen actually comes from the capecitabine, the chemotherapy backbone partner. Hand foot syndrome, diarrhea, et cetera. And so this new trial is looking at the combination of trastuzumab deruxtecan with tucatinib. So you get both of the exciting agents in one trial and drop the traditional chemotherapy backbone of capecitabine. So we’re particularly excited to enroll to this trial. We’re hoping we’re going to see a really great activity.